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Association of depressive disorders, depression
characteristics and antidepressant medication with
inflammation
N Vogelzangs1, HE Duivis2, ATF Beekman1, C Kluft3, J Neuteboom3, W Hoogendijk4, JH Smit1, P de Jonge5 and BWJH Penninx1,5,6,7
Growing evidence suggests that immune dysregulation may be involved in depressive disorders, but the exact nature of this
association is still unknown and may be restricted to specific subgroups. This study examines the association between
depressive disorders, depression characteristics and antidepressant medication with inflammation in a large cohort of controls
and depressed persons, taking possible sex differences and important confounding factors into account. Persons (18–65 years)
with a current (N¼ 1132) or remitted (N¼ 789) depressive disorder according to DSM-IV criteria and healthy controls (N¼ 494)
were selected from the Netherlands Study of Depression and Anxiety. Assessments included clinical characteristics (severity,
duration and age of onset), use of antidepressant medication and inflammatory markers (C-reactive protein (CRP), interleukin-6
(IL-6), tumor necrosis factor-alpha (TNF-a)). After adjustment for sociodemographics, currently depressed men, but not women,
had higher levels of CRP (1.33 versus 0.92mg l1, Po0.001, Cohen’s d¼ 0.32) and IL-6 (0.88 versus 0.72 pgml1, P¼ 0.01,
Cohen’s d¼ 0.23) than non-depressed peers. Associations reduced after considering lifestyle and disease indicators —
especially body mass index — but remained significant for CRP. After full adjustment, highest inflammation levels were found in
depressed men with an older age of depression onset (CRP, TNF-a). Furthermore, inflammation was increased in men using
serotonin–norepinephrine reuptake inhibitors (CRP, IL-6) and in men and women using tri- or tetracyclic antidepressants (CRP),
but decreased among men using selective serotonin reuptake inhibitors (IL-6). In conclusion, elevated inflammation was
confirmed in depressed men, especially those with a late-onset depression. Specific antidepressants may differ in their effects
on inflammation.
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Introduction
Depression is a complex heterogeneous disorder, which may
need a similarly heterogeneous offer of treatment possibilities.
Currently available antidepressant medications largely
target monoamine pathways, but treatment of depression is
only effective in about a third to a half of patients.1,2
Identification of additional pathophysiological pathways
involved in depression (subtypes) is needed to guide the
development of alternative treatment strategies. Increasing
interest has been directed to immune dysregulation in
depression. Recently, two meta-analyses have shown that
inflammatory marker levels such as C-reactive protein (CRP),
interleukin (IL)-6 and tumor necrosis factor alpha (TNF-a)
are increased in depressed persons compared with non-
depressed subjects.3,4
Although the results of these meta-analyses are promising,
the evidence for immune dysregulation in depression is not
conclusive. A substantial portion of studies included in these
meta-analyses did not adequately adjust for possible con-
founding factors. The association between depression and
inflammation appearedmuch smaller, although still present, in
studies adjusting for body mass index (BMI).4 The effect
estimate after a more complete adjustment (including several
lifestyle and disease factors) is not entirely clear. Also, most of
the larger studies examining depression and inflammation
have used depressive symptoms questionnaires instead of
assessing psychiatric diagnoses by means of clinical inter-
views. The former is much more prone to confounding by
somatic health as a person can score high on these
questionnaires based on having many physical complaints.
Furthermore, a large part of previous studies has been
conducted within older populations. More studies within
younger age samples are therefore needed.
Next to these general limitations, meta-analyses have
found very large heterogeneity across studies.3,4 It is plausible
that immune dysregulation is not generally present
in depression, but restricted to particular subgroups of
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depressed persons. Several factors that could influence the
depression–inflammation relationship need further investiga-
tion to help delineate the depressed person with immune
dysregulation. This is important to give direction to whom new
treatment strategies could be targeted.
First, sex differences might exist, but results are thus far
inconsistent. Stronger, weaker or similar effects have been
found for women compared with men for different inflamma-
tory markers.4,5 Inflammation levels fluctuate throughout
female life according to hormonal changes owing to phase
of menstrual cycle, use of hormonal contraceptives, meno-
pause and use of estrogens,6–8 which might influence the
relationship between depression and inflammation.
Second, it is largely unknown whether specific depression
characteristics indicate immune dysregulation.3 In line with a
dose-response assumption, more severe and/or more chronic
disorders can be hypothesized to show the most inflamma-
tion.9,10 In addition, late-onset depression has been asso-
ciated with family history of vascular disease7 and
atherosclerosis.11,12 As immune dysregulation is critically
involved in vascular disease,13 it can be hypothesized that
increased inflammation is specifically present in those with
late-onset depressive disorders.
Third, antidepressant medication might influence inflam-
mation levels and this effect might differ across type of
medication. As summarized by Miller et al.,14 several studies
showed that antidepressant treatment, mainly selective
serotonin reuptake inhibitors, was associated with decreases
in inflammatory markers. In contrast, recent results of two
large studies suggest that use of antidepressants, mainly
tricyclic antidepressants (TCA), is associated with elevated
inflammation levels.15
To address the issues raised above, the first aim of the
present study was to examine the association between
diagnosed depressive disorders and inflammatory markers
(CRP, IL-6 and TNF-a), using a large and relatively young
cohort of depressed persons and controls, taking possible sex
differences and important confounding factors into account.
The second aim was to investigate whether specific depres-
sion characteristics (severity, duration and age of onset) could
further delineate the depressed person with increased
inflammation. Lastly, possible effects of (specific types of)
antidepressant medication on inflammation levels were
examined.
Subjects and methods
Sample. The Netherlands Study of Depression and Anxiety
(NESDA) is an ongoing cohort study designed to investigate
the long-term course and consequences of depressive and
anxiety disorders. Participants were 18 to 65 years old at
baseline assessment in 2004–2007 and were recruited from
the community (19%), general practice (54%) and secondary
mental health care (27%). A total of 2981 persons were
included, consisting of persons with a current or past
depressive and/or anxiety disorder and healthy controls. A
detailed description of the NESDA study design and
sampling procedures can be found elsewhere.16 The
research protocol was approved by the Ethical Committee
of participating universities, and after complete description of
the study all respondents provided written informed consent.
During the baseline interview, presence of depressive
disorder (major depressive disorder, dysthymia) and anxiety
disorder (social phobia, generalized anxiety disorder,
panic disorder and agoraphobia) was established using the
Composite Interview Diagnostic Instrument (CIDI) according
to DSM-IV criteria.17 The CIDI is a highly reliable and valid
instrument for assessing depressive and anxiety disorders18
and was administered by specially trained research staff. In
addition, the severity of depression was measured in
all participants using the 28-item self-report Inventory of
Depressive Symptoms (IDS).19 For the present analyses we
selected persons with a current (that is, past 6 months;
N¼ 1158) or remitted (lifetime, but not current; N¼ 815)
depressive disorder and healthy controls without any lifetime
depressive or anxiety disorder and an IDS score below 14
(N¼ 506). Of these 2479 persons, 64 were excluded because
of missing information on inflammatory markers, leaving a
sample of 2415 persons for the present study. Persons with
missing data on inflammation did not differ from included
persons in terms of sex, age, years of education and
depressive disorder status.
Inflammatory markers. Markers of inflammation were
assessed at the baseline NESDA measurement and
included CRP, IL-6 and TNF-a. Fasting blood samples of
NESDA participants were obtained in the morning around
0800 hours and kept frozen at 70 1C. CRP and IL-6 were
assayed at the Clinical Chemistry department of the VU
University Medical Center. High-sensitivity plasma levels of
CRP were measured in duplicate by an in-house ELISA
based on purified protein and polyclonal anti-CRP antibodies
(Dako, Glostrup, Denmark). Intra- and inter-assay
coefficients of variation were 5% and 10%, respectively.
Plasma IL-6 levels were measured in duplicate by a high
sensitivity ELISA (PeliKine Compact ELISA, Sanquin,
Amsterdam, The Netherlands). Intra- and inter-assay
coefficients of variation were 8% and 12%, respectively.
Plasma TNF-a levels were assayed in duplicate at Good
Biomarker Science (Leiden, The Netherlands), using a high-
sensitivity solid phase ELISA (Quantikine HS Human TNF-a
Immunoassay, R&D systems, Minneapolis, MN, USA). Intra-
and inter-assay coefficients of variation were 10% and 15%,
respectively.
Depression characteristics. Next to CIDI depressive
disorder diagnosis, depression characteristics included
depressive symptoms severity as measured by the IDS,
and depressive symptoms duration, using the Life Chart
method,20 in which a detailed account of the presence of
depressive symptoms during the past 4 years was assessed.
From this, the percent of time patients reported depressive
symptoms was computed. Additionally, age of depression
onset was derived from the CIDI interview.
Antidepressant medication. Medication use was assessed
based on drug container inspection of all drugs used in
the past month and classified according to the World
Health Organization Anatomical Therapeutic Chemical
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classification.21 Antidepressant medication was only con-
sidered when taken on a regular basis (at least 50% of
the time) and included selective serotonin reuptake inhi-
bitors (SSRI; N06AB), serotonin–norepinephrine reuptake
inhibitors (SNRI; N06AX16 and N06AX21), TCA (N06AA)
and tetracyclic antidepressants (TeCA; N06AX03, N06AX05
and N06AX11).
Covariates. Sociodemographic characteristics included
age, sex and years of education. As lifestyle characteristics
can be associated with both depression and inflammation,
smoking status (never, former and current; assessed by self-
report), alcohol intake (o1, 1–14 (women) / 1–21 (men), 414
(women)/421 (men) drinks per week; based on general
guidelines that are used in health organizations in the
Netherlands22 and as used in other studies23), BMI (weight
in kilograms divided by height in meters squared) and
physical activity (measured with the International Physical
Activity Questionnaire24 in MET-minutes (ratio of energy
expenditure during activity compared with rest times the
number of minutes performing the activity) per week)
were assessed. In addition, several disease related
covariates were taken into account including presence of
cardiovascular disease (assessed by self-report supported
by appropriate medication use (see ref. 25 for detailed
description), presence of diabetes (fasting plasma glucose
levelX7.0mmol l1 or use of anti-diabetic medication (A10)),
and the number of other self-reported chronic diseases for
which persons received treatment (including lung disease,
osteoarthritis or rheumatic disease, cancer, ulcer, intestinal
problem, liver disease, epilepsy and thyroid gland disease).
As suggested by Howren et al.,4 to control for possible
medication effects, we assessed statin use (C10AA, C10B)
and use of systemic anti-inflammatory medication (M01A,
M01B, A07EB and A07EC). In women, we additionally
assessed use of sex hormones (self-reported use of oral
contraceptives or ATC code G03), self-reported menstrual
cycle phase (menstrual (0–3 days since start last
menstruation), follicular (4–13 days), luteal (14–32 days))
and self-reported postmenopausal status (yes/no).
Statistical analyses. All analyses were conducted using
SPSS version 15.0 statistical software (SPSS Inc., Chicago,
IL, USA). Differences in baseline characteristics across sex
were tested for statistical significance using w2-statistics for
dichotomous and categorical variables and independent t-
tests and Mann–Whitney U-tests for normally and non-
normally distributed continuous variables. For subsequent
analyses, CRP, IL-6 and TNF-a were ln-transformed to
normalize distributions and presented back-transformed.
Associations between baseline characteristics and inflam-
matory markers were tested using independent samples t-
tests for dichotomous variables, one-way analyses of
variance for categorical variables and Pearson’s corre-
lations for continuous variables.
Associations between depressive disorders and inflamma-
tory markers were examined using analyses of (co)variance
and (adjusted) means across depression groups (no, remitted
and current) were presented. To take the effects of important
confounding factors into account, three different models were
tested: unadjusted, adjusted for sociodemographics (sex, age
and education) and additionally adjusted for lifestyle and
disease (smoking status, alcohol intake, BMI, physical
activity, cardiovascular disease, diabetes, number of other
chronic diseases, statins and anti-inflammatory medication).
To investigate possible sex differences, we tested for sex
interactions by including a sex-depressive disorder interaction
term. When present, analyses were repeated sex stratified.
For significant associations, Cohen’s dwas calculated in order
to assess effect size.
To test whether specific depression characteristics were
related to elevated inflammation levels, we performed linear
regression analyses for each depression characteristic within
the sample of persons with a current depressive disorder. Sex
interactions were again tested and if present, shown sex
stratified.
To investigate possible effects of antidepressant medica-
tions, adjusted means of inflammation levels across different
medication groups were calculated using analyses of covar-
iance and presented sex stratified in case sex interaction was
present.
Results
Baseline characteristics of the total sample and for men
(N¼ 800) and women (N¼ 1615) separately are shown in
Table 1. Women were younger, less often smokers, more
often non-drinkers, had a lower BMI, less often cardiovascular
disease or diabetes and less often used statins than men. In
addition, women had higher levels of CRP, but lower levels of
IL-6 and TNF-a than men. In men, older age, less education,
smoking, heavy or non-drinking, higher BMI, lower physical
activity, cardiovascular disease, diabetes, higher number of
other chronic diseases, statin use and use of anti-inflamma-
tory medication were associated with higher levels of at least
one of the inflammatory markers (data not shown). In women,
similar associations were found, except for smoking, heavy
drinking, and physical activity. The Pearson’s correlations
between inflammatory markers were modest, likely reflecting
only partial biological overlap, and somewhat higher in men
(CRP-IL-6: r¼ 0.40; CRP-TNF-a: r¼ 0.22; IL-6–TNF-a:
r¼ 0.17) than in women (CRP-IL-6: r¼ 0.28; CRP-TNF-a:
r¼ 0.10; IL-6–TNF-a: r¼ 0.09).
Table 2 shows (adjusted) mean inflammation levels across
depression groups (controls, remitted and current depressive
disorder) based on analyses of (co) variance. In the total
sample, current depressive disorders were significantly
associated with higher levels of CRP and IL-6 in the
unadjusted model. After additional adjustment for socio-
demographics, lifestyle and disease factors, these associa-
tions disappeared. No associations were found for TNF-a. For
current depressive disorders, sex interactions were found for
CRP (P-interactiono0.001) and IL-6 (P-interaction¼ 0.009),
but not TNF-a (P-interaction¼ 0.99).
In men, after adjustment for sociodemographics, a current
depressive disorder was associated with higher CRP levels
(1.33 versus 0.92mg l1, Po0.001, Cohen’s d¼ 0.32) and
IL-6 levels (0.88 versus 0.72 pgml1, P¼ 0.01, Cohen’s
d¼ 0.23). Even after full adjustment for lifestyle and disease
factors, men with a current depressive disorder had higher
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CRP levels compared with controls (1.29 versus 1.04mg l1,
P¼ 0.02, Cohen’s d¼ 0.21), and marginally higher IL-6 levels
(0.87 versus 0.76 pgml1, P¼ 0.10, Cohen’s d¼ 0.15). No
associations with TNF-a were found in men. Overall, BMI
weakened the associations most, followed by number of other
chronic diseases. Smoking status, alcohol use and physical
activity weakened associations slightly further. Adjustment for
cardiovascular disease, diabetes, statins and anti-inflamma-
tory medication hardly affected associations.
In women, depressive disorders were not associated with
inflammatory markers before or after adjustment. Although
sex hormone use, menstrual cycle phase and postmenopausal
status were strongly associated with inflammation levels,
additional adjustment for these factors did not change the
results for women. Also, there were no significant postmeno-
pausal status-depression interactions in the associations with
inflammation levels (all P40.40) suggesting that associations
between depression and inflammation appeared absent in
both premenopausal (N¼ 1076) and postmenopausal women
(N¼ 539).
To investigate whether specific depression characteristics
(severity, duration and age of onset) were associated with
higher inflammation levels, linear regression analyses were
performed within the subgroup of currently depressed
persons (N¼ 1132; Table 3). Women with more severe
depressive symptoms had higher levels of TNF-a. No
associations were found for duration of depressive symptoms.
Menwith an older age of depression onset had higher levels of
CRP and TNF-a than those with a younger age of depression
onset.
Lastly, the association between antidepressant medication
use and inflammation levels was examined. To incorporate
possible differences in depression severity between persons
who were or were not using antidepressants, we selected a
Table 1 Baseline characteristics
Total sample
(N¼2415)
Men
(N¼800)
Women
(N¼1615)
Pa
Sociodemographics
Age (years), mean (s.d.) 41.8 (12.9) 43.7 (12.6) 40.9 (12.9) o0.001
Education (years), mean (s.d.) 12.2 (3.3) 12.0 (3.3) 12.2 (3.3) 0.12
Lifestyle and Disease
Smoking status 0.003
Never, % 27.9 23.5 30.1
Former, % 32.7 34.3 31.9
Current, % 39.4 42.3 38.0
Alcohol intake o0.001
o1 Drink a week, % 32.9 22.9 37.8
1–14 (women) / 1–21 (men) drinks a week, % 55.9 66.5 50.7
414 (women) /421 (men) drinks a week, % 11.2 10.6 11.5
Body mass index, mean (s.d.) 25.7 (5.1) 26.3 (4.6) 25.4 (5.3) o0.001
Physical activity (MET-min per week), mean (s.d.) 3673 (3026) 3758 (3324) 3630 (2867) 0.36
Cardiovascular disease, % 5.6 9.4 3.8 o0.001
Diabetes, % 4.9 7.8 3.5 o0.001
Number of other chronic diseases, mean (s.d.) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.11
Statin use, % 6.6 10.9 4.5 o0.001
Anti-inflammatory medication use, % 4.2 4.0 4.3 0.75
Depression characteristics
Depressive disorder 0.004
Controls, % 20.5 24.1 18.6
Remitted depressive disorder, % 32.7 29.8 34.1
Current depressive disorder, % 46.9 46.1 47.2
Within currently depressed cases (N¼1132)
Severity (IDS score), mean (s.d.) 32.5 (12.2) 32.9 (12.6) 32.3 (12.1) 0.46
Duration (% of time depressed), mean (s.d.) 38.5 (30.3) 40.9 (31.6) 37.4 (29.6) 0.07
Age of depression onset (years), mean (s.d.) 27.1 (12.5) 29.7 (13.3) 25.9 (11.8) o0.001
Antidepressant use 0.13
No antidepressant, % 57.2 57.5 57.1
SSRI, % 28.8 25.7 30.3
SNRI, % 7.2 9.5 6.2
TCA, % 3.8 3.5 3.9
TeCA, % 2.9 3.8 2.5
Inflammatory markers
C-reactive protein (mg l1), median (IQR) 1.22 (0.54–3.02) 1.09 (0.51–2.67) 1.30 (0.56–3.21) 0.001
Interleukin-6 (pgml1), median (IQR) 0.76 (0.50–1.25) 0.81 (0.53–1.36) 0.72 (0.49–1.19) 0.003
Tumor necrosis factor-alpha (pgml1), median (IQR) 0.80 (0.60–1.10) 0.80 (0.60–1.10) 0.70 (0.60–1.10) 0.001
Abbreviations: IDS, inventory of depressive symptoms; IQR, interquartile range; s.d., standard deviation; SSRI, selective serotonin reuptake inhibitor; SNRI,
serotonin–norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant.
aBased on w2-test for dichotomous and categorical variables, and independent samples t-test for continuous variables testing the difference between men and
women; for inflammatory markers the Mann–Whitney U-test was used.
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Table 2 Adjusted mean inflammation levels across depression groups
Controls Remitted depressive disorder Current depressive disorder
Mean (s.e.) P Mean (s.e.) P Mean (s.e.) P
CRP, mg l1, a
Total sample N¼494 N¼789 N¼ 1132
Unadjusted 1.09 (1.06) Ref 1.25 (1.04) 0.05 1.40 (1.04) o0.001
Adjustedb 1.17 (1.06) Ref 1.24 (1.04) 0.38 1.36 (1.04) 0.02
Adjustedc 1.27 (1.05) Ref 1.26 (1.04) 0.91 1.30 (1.03) 0.66
Men N¼193 N¼238 N¼ 369
Unadjusted 0.83 (1.09) Ref 1.14 (1.08) 0.005 1.36 (1.06) o0.001
Adjustedb 0.92 (1.08) Ref 1.09 (1.08) 0.13 1.33 (1.06) o0.001
Adjustedc 1.04 (1.08) Ref 1.03 (1.07) 0.96 1.29 (1.06) 0.02
Women N¼301 N¼551 N¼ 763
Unadjusted 1.29 (1.07) Ref 1.30 (1.05) 0.94 1.42 (1.05) 0.29
Adjustedb 1.36 (1.07) Ref 1.34 (1.05) 0.82 1.36 (1.05) 0.96
Adjustedc 1.45 (1.07) Ref 1.38 (1.05) 0.57 1.30 (1.04) 0.16
IL-6, pgml1, a
Total sample N¼494 N¼789 N¼ 1132
Unadjusted 0.72 (1.04) Ref 0.75 (1.03) 0.49 0.80 (1.03) 0.04
Adjustedb 0.74 (1.04) Ref 0.74 (1.03) 0.88 0.79 (1.03) 0.24
Adjustedc 0.78 (1.04) Ref 0.74 (1.03) 0.42 0.77 (1.03) 0.91
Men N¼193 N¼238 N¼ 369
Unadjusted 0.68 (1.07) Ref 0.82 (1.06) 0.03 0.89 (1.05) 0.001
Adjustedb 0.72 (1.07) Ref 0.80 (1.06) 0.20 0.88 (1.05) 0.01
Adjustedc 0.76 (1.07) Ref 0.78 (1.06) 0.72 0.87 (1.05) 0.10
Women N¼301 N¼551 N¼ 763
Unadjusted 0.74 (1.06) Ref 0.71 (1.04) 0.55 0.75 (1.04) 0.86
Adjustedb 0.77 (1.06) Ref 0.71 (1.04) 0.22 0.75 (1.03) 0.63
Adjustedc 0.80 (1.06) Ref 0.72 (1.04) 0.13 0.73 (1.03) 0.14
TNF-a, pgml1, a
Total sample N¼494 N¼789 N¼ 1132
Unadjusted 0.82 (1.03) Ref 0.82 (1.02) 0.99 0.86 (1.02) 0.23
Adjustedb 0.84 (1.03) Ref 0.82 (1.02) 0.60 0.85 (1.02) 0.59
Adjustedc 0.85 (1.03) Ref 0.82 (1.02) 0.43 0.84 (1.02) 0.78
Men N¼193 N¼238 N¼ 369
Unadjusted 0.84 (1.04) Ref 0.84 (1.04) 0.90 0.87 (1.03) 0.41
Adjustedb 0.85 (1.04) Ref 0.83 (1.04) 0.65 0.87 (1.03) 0.70
Adjustedc 0.88 (1.04) Ref 0.83 (1.04) 0.33 0.86 (1.03) 0.69
Women N¼301 N¼551 N¼ 763
Unadjusted 0.81 (1.04) Ref 0.81 (1.03) 0.97 0.85 (1.02) 0.34
Adjustedb 0.83 (1.04) Ref 0.81 (1.03) 0.76 0.84 (1.02) 0.74
Adjustedc 0.84 (1.04) Ref 0.82 (1.03) 0.70 0.83 (1.02) 0.90
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6; TNF-a, tumor necrosis factor-alpha.
aTo normalize distributions CRP, IL-6 and TNF-a were ln-transformed; for interpretation purposes presented means were back transformed.
bBased on analyses of (co)variance; adjusted for sex, age and education.
cAdditionally adjusted for smoking status, alcohol intake, body mass index, physical activity, cardiovascular disease, diabetes, number of other chronic diseases,
statins and anti-inflammatory medication.
Table 3 Associationa of depression characteristics with inflammatory markers in persons with current depressive disorders (N¼1132)
CRPb IL-6b TNF-ab
Depression characteristic b P b P b P
Severity (IDS score) 0.020 0.47 0.038 0.22 0.040 0.20
Men 0.048 0.36
Women 0.085 0.02
Duration of depressive symptoms 0.005 0.87 0.017 0.58 0.012 0.70
Age of depression onset 0.064 0.04 0.002 0.95 0.043 0.22
Men 0.140 0.003 0.149 0.004
Women 0.016 0.67 0.025 0.55
Abbreviations: CRP, C-reactive protein; IDS, inventory of depressive symptoms; IL-6, interleukin-6; TNF-a, tumor necrosis factor-alpha.
aBased on linear regression analyses adjusted for (sex), age, education, smoking status, alcohol intake, body mass index, physical activity, cardiovascular disease,
diabetes, number of other chronic diseases, statins, anti-inflammatory medication; sex-specific associations are shown in case P sex interactionp0.05.
bCRP, IL-6 and TNF-a were ln-transformed to normalize distributions.
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control group of medication-free depressed persons with a
current diagnosis and an IDS score X25 (N¼ 426). In this
medication-free reference group the mean IDS score was
comparable to the other medication groups. As effects of TCA
and TeCA users were comparable, they were grouped
together to increase numbers. Sex interactions in the
association between antidepressant medication group (no
medication, SSRI, SNRI and TCA/TeCA) and inflammatory
markers were found (CRP: P-interaction¼ 0.06, IL-6:
P-interaction¼ 0.02; TNF-a: P-interaction¼ 0.90). Therefore,
Figure 1 shows adjustedmean inflammation levels comparing
antidepressant users with medication-free persons, for men
and women separately. Increased levels of CRP were found
for men using SNRI (1.98 versus 1.21mg l1, P¼ 0.02,
Cohen’s d¼ 0.44) or TCA/TeCA (2.05 versus 1.21mg l1,
P¼ 0.02, Cohen’s d¼ 0.48) as compared with medication-
free depressed men. A trend for higher CRP in TCA/TeCA
users was also found for women (2.10 versus 1.53mg l1,
P¼ 0.08, Cohen’s d¼ 0.28). In men only, IL-6 levels were
lower in SSRI users (0.70 versus 0.91 pgml1, P¼ 0.02,
Cohen’s d¼0.32) and considerably increased in SNRI
users (1.37 versus 0.91 pgml1, P¼ 0.01, Cohen’s d¼ 0.49)
compared with medication-free depressed men. No associa-
tions were found for TNF-a. For comparison, inflammation
levels in persons with cardiovascular disease were
1.84mg l1 for CRP and 1.06 pgml1 for IL-6, suggesting
that the putative effects of antidepressant medication are at
least of similar magnitude as having cardiovascular disease.
As antidepressantmedication effects were found, we checked
whether these influenced the findings fromTables 2 and 3, but
results remained similar after additional adjustment for
antidepressant medication group.
Discussion
The present study examined the association between
depressive disorders, depression characteristics and anti-
depressant medication with inflammation in a large cohort of
depressed persons and controls. After taking a large set of
possibly confounding factors into account, it was found that
men with current depressive disorders had higher levels of
CRP, and marginally higher levels of IL-6, but not of TNF-a.
No overall associations were found in women. Increased
inflammation was in particular found in depressedmenwith an
older age of depression onset (CRP, TNF-a). Users of SNRI
(men only), TCA and TeCA had increased levels of CRP
and IL-6, whereas men using SSRI had significantly lower
levels of IL-6.
Our results confirm previous findings of immune dysregula-
tion in depressed persons.3,4 In men, effect sizes for current
depression were small to moderate for both CRP and IL-6.
These effect sizes are comparable to those reported by the
meta-analysis of Howren,4 in which stronger effects were
found for studies using clinical interviews compared with
studies using self-report questionnaires. Compared with
symptom questionnaires, a depressive disorder diagnosis is
less confounded by somatic health problems. Together with
the fact that our results were elaborately adjusted for possibly
confounding factors, our findings suggest a true relationship
between depression and inflammation in men.

Figure 1 Adjusted mean inflammatory levels across medication groups and sex
based on analyses of covariance (ANCOVA) adjusted for age, education, smoking
status, alcohol intake, body mass index (BMI), physical activity, cardiovascular
disease, diabetes, number of other chronic diseases, statins and anti-inflammatory
medication; to normalize distributions C-reactive protein (CRP), Interleukin-6 (IL-6)
and Tumor necrosis factor-alpha (TNF-a) were ln-transformed, for interpretation
purposes presented means were back transformed. Abbreviations: IDS, inventory of
depressive symptoms score; SNRI, serotonin–norepinephrine reuptake inhibitor;
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; TeCA,
tetracyclic antidepressant. 1Current depressive disorder and IDS X25 without
medication use (¼ reference); only significant differences from reference are
shown: *Po0.10; **Po0.05.
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No clear associations between depression and inflamma-
tion were found in women. This is in line with results from
another large and relatively young cohort study in which
history of depression was associated with CRP levels in men,
but not women.5 Hormonal changes throughout female
life due to phase of menstrual cycle, use of hormonal
contraceptives, menopause and use of estrogens greatly
impact on inflammation levels,6–8 which could confound a
clear association between depression and inflammation.
However, in our study, associations between depression
and inflammation appeared absent in both pre- and post-
menopausal women and adjusting for several hormonal
factors did not change our findings. Another explanation
might be that in women, psychosocial factors have a larger
role in depression and therefore override the effects of
biological factors. For instance, insufficient social support
and stressful life events have been found to pose a greater risk
for depression among women compared with men.26,27
Results of increased inflammation were particularly present
in men with late-onset depression. In contrast, characteristics
that are more often associated with an early age of onset,
such as higher severity and longer duration, were not
consistently associated with increased inflammation. Inter-
esting to note is that women in our study also had an earlier
age of depression onset compared with men. A distinct
etiology in late-onset versus early-onset depression was also
found by Kendler et al.28 This study showed that depression
with an early age of onset was associated with a family history
of depression, whereas late-onset depression was associated
with a family history of vascular disease. Also, subclinical
vascular dysregulations, such as atherosclerosis, have been
found to relate to late-onset depression.11,12 These findings
are in line with the vascular depression hypothesis, which
suggests that vascular damage in the brain predisposes to
late-onset depression.29 As immune dysregulation is critically
involved in vascular disease,13 this vascular damage could be
the result of increased inflammation.
Instead of inflammatory or vascular, the true etiology of
depression in this subgroup of men with late-onset depression
might have a metabolic nature. Several studies have
confirmed an association between CRP, IL-6 and TNF-a with
the metabolic syndrome and visceral fat depots release
cytokines.30 The metabolic syndrome and in particular
visceral fat have been bidirectionally associated with depres-
sion in late life,31,32 specifically in men. Men possess higher
amounts of visceral fat compared with women and are
therefore more likely to experience related inflammation and
depression. Involvement of metabolic processes is further
supported by our finding that the association between
depression and inflammation in particular decreased after
adjustment for BMI.
Several biological mechanisms could further explain the
relationship between depression and inflammation. Depres-
sion has been associated with dysregulation of important
stress systems of the human body, that is, the hypothalamus–
pituitary–adrenal-axis33 and the autonomic nervous system.34
Although the hypothalamus–pituitary–adrenal-axis in normal
situations should temper inflammatory reactions, prolonged
hyperactivity of the hypothalamus–pituitary–adrenal-axis
could result in blunted anti-inflammatory responses to
glucocorticoids resulting in increased inflammation.35,36 In
addition, both decreased parasympathetic37 as well as
increased sympathetic nervous system activity38 have been
associated with increased inflammation. Furthermore, pro-
inflammatory cytokines might inhibit hippocampal neurogen-
esis,39 which could lead to a reduced hippocampal volume,40
which is also seen in depression.41 Also, several inflammatory
markers have been shown to promote indoleamine-2,3-
dioxygenase activation,42 which catalyzes tryptophan, the
precursor of serotonin, to kynurenine, thereby indirectly
reducing the availability of serotonin.43 Lastly, specific genes
might underlie both increased inflammation and depression,
as several inflammation-related genes have been associated
with susceptibility to major depression.44
Our study also shows that inflammation levels differ across
persons using different types of antidepressant medication.
The highest inflammation levels were found in men using
SNRI, TCA or TeCA, while IL-6 levels in men using SSRI were
lower compared with medication-free depressed men. Inter-
esting to note is that the first three classes of medication have
a combined serotonergic/noradrenergic effect, whereas SSRI
act purely serotonergic. Earlier studies found decreases in
inflammatory marker levels after antidepressant treatment,
mainly SSRI (see ref. 14 for an overview), whereas two recent
large studies found that use of antidepressants, mainly TCA,
was associated with elevated inflammation levels.15 Possibly,
noradrenergic effects are driving increased inflammation
mechanisms. Noradrenaline is a part of the human stress
response and has been suggested to potentiate cytokine
production.45 Use of SNRI, TCA and TeCA has also been
observed to disturb functioning of autonomic nervous sys-
tem,46 blood pressure47 and the metabolic syndrome.48
Although it is possible that persons using SNRI, TCA or
TeCA are in other ways different from SSRI users and
medication-free depressed persons, we constructed our
groups in such a way that depression severity levels were
very comparable. In addition, we adjusted our analyses for a
large set of covariates and have therefore taken possible
differences in lifestyle or disease factors into account. On the
other hand, evidence suggests that increased inflammatory
activity before treatment predicts non-response.49,50 Possi-
bly, persons with elevated inflammation did not respond to
SSRI and were therefore prescribed SNRI, TCA or TeCA.
Associations found in this study were not always consistent
across all inflammatory markers. Correlations between
inflammatory markers were only modest and were highest
between CRP and IL-6. Regulation of the immune system is
rather complex and involves many different inflammatory
mechanisms. Most consistent findings were found for CRP,
which is a very general marker of inflammation. IL-6 andTNF-a,
on the other hand, only tap part of the immune system. This
seems to suggest that inflammation is indeed involved in
depression, but it is still unclear which part of the immune
system is most critically involved. Nonetheless, expected
associations with covariates (for example, age, smoking,
alcohol use, BMI, physical activity and somatic disease
(medication)) were found for all inflammatory markers.
What do the findings of our study implicate with regard to
treatment of depression? Considering the heterogeneity of
depression and the fact that current treatment of depression is
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only effective in about a third to a half of patients,1,2 this
indicates that new treatments are needed for specific
subgroups. Our finding of increased inflammation in men with
late-onset depression, together with previous findings of high
inflammation indicating non-response to antidepressants,49,50
might suggest that this specific subgroup could benefit from
alternative treatments, with anti-inflammatory medication
being a likely candidate. Preliminary evidence from studies
among patients treated with anti-inflammatory agents for other
indications suggests that these agents may have beneficial
effects onmood.51One study found positive effects onmood in
medically healthy, major depressed patients.52 On the other
hand we found, like others,14 that SSRImight have a beneficial
effect on inflammation, suggesting that SSRI could be effective
in depressed patients with immune dysregulation through this
anti-inflammatory effect. Furthermore, behavioral interven-
tions, such as exercise, have been shown to normalize
immune and metabolic dysregulation,53 as well as to improve
depressive symptoms to some degree,54 and might therefore
be an indicated treatment for a immune/metabolic depression
subgroup. At this moment, these considerations for treatment
implications are still very speculative. Follow-up (longitudinal)
research should confirm and further delineate an inflammatory
(or metabolic) depression subtype, taking into account age,
sex, depression characteristics and course. Experimental
studies are needed to examine and compare the effects of
different types of currently available antidepressants, anti-
inflammatory medication and behavioral (exercise) interven-
tions on both immune/metabolic parameters and depression.
Our study has some important strengths such as a large
sample size, assessment of multiple inflammatory markers,
clinical diagnoses of depression, adequate adjustment for
potential confounders, the ability to examine the role of
depression characteristics and antidepressant medication.
However, some limitations need to be acknowledged. As our
data are cross-sectional, we cannot make any inferences
about the direction of the association. Longitudinal studies are
needed to investigate whether immune dysregulation is a
precursor or the result of depression (treatment), or whether
this relationship is bidirectional. The few available prospective
studies have shown contradicting results.9,55,56 Further, like
most other studies, we assessed circulating levels of inflam-
matory markers, which show a high degree of intra-individual
variation, which could explain the rather modest overall
associations between depression and inflammation in our
study.
In conclusion, our study suggests that immune dysregula-
tion has a role in a subgroup of depressed persons, in
particular in men with a late-onset depression. Treatment
trials should further examine the differential effects of different
types of antidepressants on inflammation. Whether a specific
treatment strategy (SSRI, anti-inflammatory drugs, exercise)
is indicated for a subgroup of late-onset depressed patients
with immune dysregulation needs to be further investigated,
using longitudinal and experimental study designs.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements. The infrastructure for the NESDA study
(www.nesda.nl) is funded through the Geestkracht program of the Netherlands
Organization for Health Research and Development (Zon-Mw, grant number 10-
000-1002) and is supported by participating universities and mental health care
organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden University
Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis,
GGZ Friesland, GGZ Drenthe, Institute for Quality of Health Care (IQ Healthcare),
Netherlands Institute for Health Services Research (NIVEL) and Netherlands
Institute of Mental Health and Addiction (Trimbos). Data analyses were supported
through a fellowship (NV) from the EMGO Institute for Health and Care Research.
Assaying of inflammatory markers was supported by the Neuroscience Campus
Amsterdam.
1. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of
antidepressants: current status of research. Psychother Psychosom 2010; 79: 267–279.
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al. Acute
and longer-term outcomes in depressed outpatients requiring one or several treatment
steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–1917.
3. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of
cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.
4. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1,
and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171–186.
5. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and
elevated C-reactive protein. Psychosom Med 2003; 65: 347–356.
6. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL et al. Effect of
postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal
Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717–722.
7. Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma
concentration of C-reactive protein. Life Sci 2003; 73: 1245–1252.
8. Jilma B, Dirnberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG et al. Menstrual
cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-
reactive protein. J Lab Clin Med 1997; 130: 69–75.
9. Duivis HE, de JP, Penninx BW, Na BY, Cohen BE, Whooley MA. Depressive symptoms,
health behaviors, and subsequent inflammation in patients with coronary heart disease:
prospective findings from the heart and soul study. Am J Psychiatry 2011; 168: 913–920.
10. Hamer M, Molloy GJ, de OC, Demakakos P. Persistent depressive symptomatology and
inflammation: to what extent do health behaviours and weight control mediate this
relationship? Brain Behav Immun 2009; 23: 413–418.
11. Seldenrijk A, van Hout HP, van Marwijk HW, de GE, Gort J, Rustemeijer C et al. Carotid
atherosclerosis in depression and anxiety: Associations for age of depression onset.World
J Biol Psychiatry 2011; 12: 549–558.
12. Smith PJ, Blumenthal JA, Babyak MA, Doraiswamy PM, Hinderliter A, Hoffman BM et al.
Intima-media thickness and age of first depressive episode. Biol Psychol 2009; 80:
361–364.
13. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;
109(21 Suppl 1): II2–II10.
14. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in
the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732–741.
15. Hamer M, Batty GD, Marmot MG, Singh-Manoux A, Kivimaki M. Anti-depressant
medication use and C-reactive protein: results from two population-based studies. Brain
Behav Immun 2011; 25: 168–173.
16. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P et al. The
Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and
methods. Int J Methods Psychiatr Res 2008; 17: 121–140.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders,
fourth edition. 4th edn. American Psychiatric Association: Washington, DC, 2001.
18. Wittchen HU. Reliability and validity studies of the WHO–Composite International
Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 1994; 28: 57–84.
19. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive
Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477–486.
20. Lyketsos CG, Nestadt G, Cwi J, Heithoff K, Eaton WW. The life chart interview: A
standardized method to describe the course of psychopathology. Int J Methods Psychiatr
Res 1994; 4: 143–155.
21. WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic
Chemical Classification. World Health Organization: Geneva, 2007.
22. Stuurgroep Multidisciplinaire Richtlijnontwikkeling. Stoornissen in het gebruik van alcohol:
Richtlijn voor de diagnostiek en behandeling van patie¨nten met een stoornis in het gebruik
van alcohol. GGZ: Utrecht, The Netherlands, 2009.
23. Gianoulakis C, Dai X, Brown T. Effect of chronic alcohol consumption on the activity of the
hypothalamic-pituitary-adrenal axis and pituitary beta-endorphin as a function of alcohol
intake, age, and gender. Alcohol Clin Exp Res 2003; 27: 410–423.
24. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al.
International physical activity questionnaire: 12-country reliability and validity. Med Sci
Sports Exerc 2003; 35: 1381–1395.
Depression and inflammation
N Vogelzangs et al
8
Translational Psychiatry
25. Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de JP, Penninx BW.
Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord
2010; 125: 241–248.
26. Kendler KS, Myers J, Prescott CA. Sex differences in the relationship between social
support and risk for major depression: a longitudinal study of opposite-sex twin pairs. Am J
Psychiatry 2005; 162: 250–256.
27. Maciejewski PK, Prigerson HG, Mazure CM. Sex differences in event-related risk for major
depression. Psychol Med 2001; 31: 593–604.
28. Kendler KS, Fiske A, Gardner CO, Gatz M. Delineation of two genetic pathways to major
depression. Biol Psychiatry 2009; 65: 808–811.
29. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. Vascular
depression’ hypothesis. Arch Gen Psychiatry 1997; 54: 915–922.
30. Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab
Syndr Relat Disord 2004; 2: 82–104.
31. Vogelzangs N, Kritchevsky SB, Beekman AT, Newman AB, Satterfield S, Simonsick EM
et al. Depressive symptoms and change in abdominal obesity in older persons. Arch Gen
Psychiatry 2008; 65: 1386–1393.
32. Vogelzangs N, Kritchevsky SB, Beekman AT, Brenes GA, Newman AB, Satterfield S et al.
Obesity and onset of significant depressive symptoms: results from a prospective community-
based cohort study of older men and women. J Clin Psychiatry 2010; 71: 391–399.
33. Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, Van DR et al. Major
depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large
cohort study. Arch Gen Psychiatry 2009; 66: 617–626.
34. Licht CM, de Geus EJ, Zitman FG, Hoogendijk WJ, Van DR, Penninx BW. Association
between major depressive disorder and heart rate variability in the Netherlands Study of
Depression and Anxiety (NESDA). Arch Gen Psychiatry 2008; 65: 1358–1367.
35. Miller GE, Cohen S, Ritchey AK. Chronic psychological stress and the regulation of pro-
inflammatory cytokines: a glucocorticoid-resistance model.Health Psychol 2002; 21: 531–541.
36. Wirtz PH, von KR, Schnorpfeil P, Ehlert U, Frey K, Fischer JE. Reduced glucocorticoid
sensitivity of monocyte interleukin-6 production in male industrial employees who are vitally
exhausted. Psychosom Med 2003; 65: 672–678.
37. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is
inversely related to inflammatory markers: the CARDIA study.Mol Med 2007; 13: 178–184.
38. Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN et al.
Catecholamines mediate stress-induced increases in peripheral and central inflammatory
cytokines. Neuroscience 2005; 135: 1295–1307.
39. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for
neurogenesis in adult brain. Proc Natl Acad Sci USA 2003; 100: 13632–13637.
40. Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries
inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry
2008; 64: 484–490.
41. Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in
patients suffering from depression: a meta-analysis. Am J Psychiatry 2004; 161: 598–607.
42. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H et al. The signal transducer
and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for
the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38
mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic
effect of several proinflammatory cytokines. J Biochem 2006; 139: 655–662.
43. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to
sickness and depression: when the immune system subjugates the brain. Nat Rev
Neurosci 2008; 9: 46–56.
44. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related
genes are associated with susceptibility to major depression and antidepressant response.
Mol Psychiatry 2008; 13: 800–812.
45. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory
cytokines, and autoimmunity. Ann N Y Acad Sci 2002; 966: 290–303.
46. Licht CM, de Geus EJ, Van DR, Penninx BW. Longitudinal evidence for unfavorable effects
of antidepressants on heart rate variability. Biol Psychiatry 2010; 68: 861–868.
47. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, Van DR et al. Depression is
associated with decreased blood pressure, but antidepressant use increases the risk for
hypertension. Hypertension 2009; 53: 631–638.
48. van Reedt Dortland AK, Giltay EJ, van VT, Zitman FG, Penninx BW. Metabolic syndrome
abnormalities are associated with severity of anxiety and depression and with tricyclic
antidepressant use. Acta Psychiatr Scand 2010; 122: 30–39.
49. Lanquillon S, Krieg JC, ing-Abu-Shach U, Vedder H. Cytokine production and
treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22:
370–379.
50. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to
escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry
2008; 32: 445–450.
51. Muller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 inhibitors–a possible new
approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004;
37: 266–269.
52. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al. The
cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of
a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol
Psychiatry 2006; 11: 680–684.
53. You T, Nicklas BJ. Effects of exercise on adipokines and the metabolic syndrome. Curr
Diab Rep 2008; 8: 7–11.
54. Mead GE, Morley W, Campbell P, Greig CA, McMurdo M, Lawlor DA. Exercise for
depression. Cochrane Database Syst Rev 2009; CD004366.
55. Gimeno D, Kivimaki M, Brunner EJ, Elovainio M, De VR, Steptoe A et al. Associations of C-
reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up
of the Whitehall II study. Psychol Med 2009; 39: 413–423.
56. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the
directionality of the depression-inflammation relationship. Brain Behav Immun 2009; 23:
936–944.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
Derivative Works 3.0 Unported License. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Depression and inflammation
N Vogelzangs et al
9
Translational Psychiatry
